Summary
In recent years, different therapeutic approaches have emerged for individualized targeted therapy in tumour patients. It was found that tumours derived from neuroendocrine tissue frequently show somatostatin receptor (SSTR) expression. This property has proven usefulness for imaging neuroendocrine tumours in different clinical situations, e.g. for initial diagnosis and staging, with high diagnostic efficacy. On the basis of these findings tumours were also treated by radiopharmaceuticals showing promising overall results. At our department, patients are selected for radionuclide therapy by their inherent biological characteristic, which can be evaluated by scintigraphy using either with DOTA-TOC or, if this scan is negative, with DOTA-LAN. Recently, these compounds were also labelled with Gallium-68 for PET imaging, providing higher diagnostic quality for initial evaluation and also for follow-up scanning after radionuclide therapy. Individualized therapy in nuclear medicine requires especially optimal functional imaging techniques with PET for visual evaluation and scintigraphy with In-111 labelled compounds for dosimetry. According to our protocol ("Innsbruck Protocol") for peptide receptor radionuclide-therapy with differently labelled tracers (Y-90 or Lu-177) and somatostatin (SST) analogues used, only few serious side effects were observed and therapy was generally well tolerated. These results favour the combined use of radiolabelled SST analogues providing a customized tumour targeting for size reduction and improvement of quality of life. Reduced individual doses make sense in patients with advanced tumour stages, in case of moderate SSTR-expression, and in patients with higher age. Adverse reactions were seen especially in patients who were treated with high doses per cycle, in patients pre-treated with chemotherapy and in patients with low clinical performance index.
Similar content being viewed by others
References
Kwekkeboom DJ, Krenning EP, Bakker WH, et al. Somatostatin analogue scintigraphy in carcinoid tumours. Eur J Nucl Med, 20: 283–292, 1993
Joseph K, Stapp J, Reinecke J, et al. Receptor scintigraphy with 111 In-pentetreotide for endocrine gastroenteropancreatic tumors. Horm Metab Res, 27(Suppl): 28–35, 1993
Olsen JO, Pozderac RV, Hinkle G, et al. Somatostatin receptor imaging of neuroendocrine tumours with indium-111-pentetreotide (OctreoScan). Semin Nucl Med, 25: 251–261, 1995
Jamar F, Fiasse R, Leners N, Pauwels S. Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safty, efficacy and impact on patient management. J Nucl Med, 36: 542–549, 1995
Lebtahi R, Cadiot G, Sarda L, et al. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J Nucl Med, 38: 853–858, 1997
Kisker O, Bartsch D, Weinel RJ, et al. The value of somatostatin-receptor scintigraphy in newly diagnosed endocrine gastroenteropancreatic tumors. J Am Coll Surg, 184: 487–492, 1997
Seregni E, Chiti A, Bombardieri E. Radionuclide imaging of neuroendocrine tumours: biological basis and diagnostic results. Eur J Nucl Med, 25: 639–658, 1998
Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med, 20: 716–731, 1998
Frilling A, Malago M, Martin H, Broelsch CE. Use of somatostatin receptor scintigraphy to image extrahepatic metastases of neuroendocrine tumors. Surgery, 124: 1000–1004, 1998
Krausz Y, Bar-Ziv J, De Jong R, et al. Somatostatin receptor scintigraphy in the management of gastroenteropancreatic tumors. Am J Gastroenterol, 93: 66–70, 1998
Chiti A, Briganti V, Fanti S, et al. Results and potential of somatostatin receptor imaging in gastroenteropancreatic tract tumours. Q J Nucl Med, 44: 42–49, 2000
Gotthardt M, Dirkmorfeld LM, Wied MU, et al. Influence of somatostatin receptor scintigraphy and CT/MRI on the clinical management of patients with gastrointestinal neuroendocrine tumors: an analysis in 188 patients. Digestion, 68: 80–85, 2003
Reubi J-C, Häcki WH, Lamberts SWJ. Hormones producing gastrointestinal tumors contain a high density of somatostatin receptors. J Clin Endocrinol Metab, 65: 1127–1134, 1987
Gabriel M, Decristoforo C, Donnemiller E, et al. An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111 In-DTPA-octreotide for diagnosis of somatostatin receptor expressing tumors. J Nucl Med, 44: 708–716, 2003
Van Essen M, Krenning EP, De Jong M, Valkema R, Kwekkeboom DJ. Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncol, 46: 723–734, 2007
Kwekkeboom DJ, Teunissen JJ, Bakker WH, et al. Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate in patients with endocrine gastropancreatic tumors. J Cin Oncol, 23: 2754–2762, 2005
Teunissen JJ, Kwekkeboom DJ, Krenning EP. Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0, Tyr3]octreotate. J Clin Oncol, 22: 2724–2729, 2004
Gabriel M, Muehllechner P, Decristoforo C, et al. 99mTc-EDDA/HYNIC-Tyr(3)-octreotide for staging and follow-up of patients with neuroendocrine gastro-entero-pancreatic tumors. Q J Nucl Med Mol Imaging, 49: 237–244, 2005
Plachcinska A, Mikolajczak R, Maecke HR, et al. Clinical usefulness of 99mTc-EDDA/HYNIC-TOC scintigraphy in oncological diagnostic: a preliminary communication. Eur J Nucl Med Mol Imaging, 30: 1402–1406, 2003
Plachcinska A, Mikolajczak R, Maecke HR, et al. Clinical usefulness of 99mTc-EDDA/HYNIC-TOC scintigraphy in oncological diagnostics: a pilot study. Cancer Biother Radiopharm, 19: 261–270, 2004
Parisella MG, D'Alessandria C, van de Bossche B, et al. 99mTc-EDDA/HYNIC-TOC in the management of medullary thyroid carcinoma. Cancer Biother Radiopharm, 19: 211–217, 2004
Hubalewsska-Dydejczyk A, Froess-Baron K, et al. 99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years' experience. Eur J Nucl Med Mol Imaging, 33: 1123–1133, 2006
Czepczynski R, Parisella MG, Kosowicz J, et al. Somatostatin receptor scintigraphy using 99mTc-EDDA/HYNIC-TOC in patients with medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging, 34: 1635–1645, 2007
Hubalewska-Dydejczyk A, Kulig J, Szybinski P, et al. Radio-guided surgery with the use of [99mTc-EDDA/HYNIC]octreotate in intra-operative detection of neuroendocrine tumours of the gastrointestinal tract. Eur J Nucl Med Mol Imaging, 34: 1545–1555, 2007
Gabriel M, Hausler F, Bale R, et al. Image fusion analysis of (99m)Tc-HYNIC-Tyr(3)-octreotide SPECT and diagnostic CT using an immobilisation device with external markers in patients with endocrine tumours. Eur J Nucl Med Mol Imaging, 32: 1440–1451, 2005
Gabriel M, Decristoforo C, Kendler C, et al. 68Gallium-DOTA-Tyr(3)-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Nucl Med, 48: 508–518, 2007
Gabriel M, Andergassen U, Putzer D, Decristoforo C, et al. Innsbruck experience with targeted radionuclide therapy using different radiolabeled somatostatin analogs. Eur J Nucl Med Mol Imaging, 34(Suppl 2): S220, 2007
Lamberts S, Bakker W, Reubi JC, Krenning E. Somatostatin receptor imaging in the localization of endocrine tumours. N Engl J Med, 323: 1246–1249, 1990
Krenning E, Bakker W, Breeman W, et al. Localization of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet, 1: 242–244, 1989
Rodrigues M, Traub-Weidinger T, Li S, Ibi B, Virgolini I. Comparison of 111In-DOTA-D-Phe1-Tyr3-octreotide and 111In-DOTA-lanreotide scintigraphy and dosimetry in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging, 33: 532–540, 2006
De Jong M, Bernard B, De Bruin E, et al. Internalization of radiolabelled [DTPA0]octreotide and [DOTA0, Tyr3]octreotide: peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy. Nucl Med Comm, 19: 283–288, 1998
De Jong M, Breeman WA, Valkema R, Bernard BF, Krenning EP. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. J Nucl Med, 46(Suppl 1): 13S–17S, 2005
Gabriel M, Oberauer A, Kendler D, et al. Comparison of 68Ga-DOTA-Tyr(3)-Octreotide PET and diagnostic CT for treatment evaluation of radionuclide therapy. Eur Radiol, 18(Suppl 1): S326, 2008
Jaffe CC. Measures of response: RECIST, WHO, and new alternatives. J Clin Oncol, 24: 3245–3251, 2006
Lordick F, Ott K, Krause BJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogstric junction: the MUNICON phase II trial. Lancet Oncol, 8: 797–805, 2007
Gabriel M, Hausler F, Bale R, et al. Image fusion analysis of (99m)Tc-HYNIC-Tyr(3)-octreotide SPECT and diagnostic CT using an immobilisation device with external markers in patients with endocrine tumours. Eur J Nucl Med Mol Imaging, 32: 1440–1451, 2005
Ezziddin S, Logvinski T, Yong-Hing C, et al. Factors predicting tracer uptake in somatoststin receptor and MIBG scintigraphy of metastatic gastroeenteropancreatic neuroendocrine tumors. J Nucl Med, 47: 223–233, 2006
Le Rest C, Bomanji JB, Costa DC, Townsend CE, Visvikis D, Ell PJ. Functional imaging of malignant paragangliomas and carcinoid tumours. Eur J Nucl Med, 28: 478–482, 2001
Adams S, Baum R, Rink T, Schumm-Draeger PM, Usadel KH, Hoer G. Limited value of fluorine-18 flourodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med, 25: 79–83, 1998
Belhocine T, Foidart J, Rigo P, et al. Fluorodeoxyglucose positron emission tomography and somatostatin receptor scintigraphy for diagnosing and staging characinoid tumours: correlations with the pathological indexes p53 and Ki-67. Nucl Med Comm, 23: 727–734, 2002
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gabriel, M., Andergassen, U. & Virgolini, I. Individualized molecular cancer therapy based on radiolabelled somatostatin analogues. memo 1, 171–175 (2008). https://doi.org/10.1007/s12254-008-0056-8
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s12254-008-0056-8